TABLE 1.

Timeline of patient.

October 23, 2015	She presented at the emergency department outside the hospital with transient loss of consciousness, difficulty in walking, proximal weakness in leg, and dysarthria.
October 29, 2015	Subsequent investigations were s/o‐Grade III Follicular lymphoma, stage IV on the Ann Arbor staging system. FLIPI was 4
November 14, 2015	Started chemotherapy with Rituximab (Inj. Restova 500 mg)
November 24, 2015	Started Rasayan therapy, received 3 cycles of chemotherapy. However, post cycles suffered from ADRs like cardiac toxicity (CTCAE Grade III), Lung Infection (CTCAE V5 –Grade III), Oral Mucositis (CTCAE V5Gr II), and hematological toxicity (CTCAE Grade II)
January 6, 2016	Due to intolerance, chemotherapy had to be discontinued. Patient's prognosis was poor. Further, she was treated with exclusive Rasayana therapy from 06 January 2016 for 41 months. ART is tolerated well by the patient. Tumor response was observed along with improvement in quality of life physical performance status. The patient showed a survival of 3.5 years after starting ART.